In PIONEER-HF, NT-proBNP-guided therapy in hospitalized, stabilized patients improved outcomes; however, long-term outcome comparisons between in-hospital versus post-discharge initiation remain limited, particularly regarding readmission risk and therapy responsiveness [93]. The gene discussed is NPPB; the disease is hydrops fetalis.